Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flucloxacillin with probenecid or ibuprofen in healthy adults
ACTRN12623001155684Phase 4Completed
- Sponsor
- University of Melbourne
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of flucloxacillin, probenecid and ibuprofen in Staphylococcus aureus infection and bacterial disease (2 arms), sponsored by University of Melbourne. Primary endpoints: Effect of probenecid on oral flucloxacillin pharmacokinetics in serum and urine and Effect of ibuprofen on intravenous flucloxacillin pharmacokinetics in serum and urine. Started Jan 2024; status: completed.
02
Drugs
flucloxacillinprobenecidibuprofen
03
Conditions
Staphylococcus aureus infectionbacterial disease
Beyond the preview
Go deeper on ACTRN12623001155684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001155684.